Compare MKL & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKL | WAT |
|---|---|---|
| Founded | 1930 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 29.3B |
| IPO Year | 1999 | 1996 |
| Metric | MKL | WAT |
|---|---|---|
| Price | $1,957.02 | $317.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 16 |
| Target Price | ★ $2,100.00 | $382.47 |
| AVG Volume (30 Days) | 46.0K | ★ 887.4K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | ★ 169.22 | 10.76 |
| Revenue | ★ $15,513,233,000.00 | $3,165,286,000.00 |
| Revenue This Year | N/A | $104.66 |
| Revenue Next Year | $2.22 | $10.42 |
| P/E Ratio | ★ $11.52 | $29.70 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $1,698.99 | $275.05 |
| 52 Week High | $2,207.59 | $414.15 |
| Indicator | MKL | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 58.17 |
| Support Level | $1,948.00 | $282.76 |
| Resistance Level | $1,999.37 | $323.29 |
| Average True Range (ATR) | 33.74 | 9.01 |
| MACD | 12.06 | 4.18 |
| Stochastic Oscillator | 84.55 | 83.93 |
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.